AIMS: To investigate association of the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene with clinical features in Serbian patients with Parkinson's disease (PD). METHODS: The study comprised 177 consecutive PD patients. A comprehensive set of clinical scales was applied in all patients. The controls (n=366) were recruited among students. Single nucleotide polymorphisms (SNPs; rs6265) were analyzed using TaqMan assays. RESULTS: PD patients (118 males) were aged 58.9±10.9 years, with a mean age at onset of 49.0±11.2 years. PD patients and controls had a similar distribution of genotypes and allele frequencies. The presence of the Met allele did not influence the clinical characteristics of PD patients (age at onset, family history, gender, disease duration, form of the disease, initial symptoms, cognitive abilities, depression, anxiety, disease severity, severity of motor and prevalence of nonmotor symptoms, and development of motor complications). CONCLUSION: Overall, the Val66Met polymorphism did not modify the clinical features in PD patients.
AIMS: To investigate association of the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene with clinical features in Serbian patients with Parkinson's disease (PD). METHODS: The study comprised 177 consecutive PDpatients. A comprehensive set of clinical scales was applied in all patients. The controls (n=366) were recruited among students. Single nucleotide polymorphisms (SNPs; rs6265) were analyzed using TaqMan assays. RESULTS:PDpatients (118 males) were aged 58.9±10.9 years, with a mean age at onset of 49.0±11.2 years. PDpatients and controls had a similar distribution of genotypes and allele frequencies. The presence of the Met allele did not influence the clinical characteristics of PDpatients (age at onset, family history, gender, disease duration, form of the disease, initial symptoms, cognitive abilities, depression, anxiety, disease severity, severity of motor and prevalence of nonmotor symptoms, and development of motor complications). CONCLUSION: Overall, the Val66Met polymorphism did not modify the clinical features in PDpatients.
Authors: Michael Baer; Bradley Klemetson; Diana Scott; Andrew S Murtishaw; James W Navalta; Jefferson W Kinney; Merrill R Landers Journal: J Neurol Phys Ther Date: 2018-04 Impact factor: 3.649
Authors: D Luke Fischer; Peggy Auinger; John L Goudreau; Allyson Cole-Strauss; Karl Kieburtz; Jordan J Elm; Mallory L Hacker; P David Charles; Jack W Lipton; Barbara A Pickut; Caryl E Sortwell Journal: Neurotherapeutics Date: 2020-11-19 Impact factor: 7.620
Authors: Alberto Costa; Antonella Peppe; Giovanni Augusto Carlesimo; Silvia Zabberoni; Francesco Scalici; Carlo Caltagirone; Francesco Angelucci Journal: Front Behav Neurosci Date: 2015-09-15 Impact factor: 3.558